OPKO Health (NASDAQ:OPK) vs. Progyny (NASDAQ:PGNY) Critical Review

Progyny (NASDAQ:PGNY) and OPKO Health (NASDAQ:OPK) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Risk & Volatility

Progyny has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Progyny and OPKO Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0	4	9	0	2.69
OPKO Health	1	2	4	1	2.62

Progyny currently has a consensus price target of $34.36, suggesting a potential upside of 20.83%. OPKO Health has a consensus price target of $2.96, suggesting a potential upside of 85.16%. Given OPKO Health’s higher probable upside, analysts clearly believe OPKO Health is more favorable than Progyny.

Insider and Institutional Ownership

94.9% of Progyny shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 44.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Progyny and OPKO Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29 billion	1.69	$58.52 million	$0.92	30.91
OPKO Health	$606.90 million	1.97	-$225.68 million	($0.09)	-17.78

Progyny has higher revenue and earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Progyny and OPKO Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
OPKO Health	-12.40%	-5.88%	-3.83%

Summary

Progyny beats OPKO Health on 10 of the 15 factors compared between the two stocks.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.